158 related articles for article (PubMed ID: 12849674)
21. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4).
O'Connor CM; Gattis WA; Adams KF; Shah MR; Kobrin I; Frey A; Gheorghiade M
Am Heart J; 2002 Oct; 144(4):583-8. PubMed ID: 12360152
[TBL] [Abstract][Full Text] [Related]
22. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
Qiu CB; Qiu CS; Hess P; Clozel JP; Clozel M
Acta Pharmacol Sin; 2001 Jun; 22(6):541-8. PubMed ID: 11747762
[TBL] [Abstract][Full Text] [Related]
23. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).
Lüscher TF; Enseleit F; Pacher R; Mitrovic V; Schulze MR; Willenbrock R; Dietz R; Rousson V; Hürlimann D; Philipp S; Notter T; Noll G; Ruschitzka F;
Circulation; 2002 Nov; 106(21):2666-72. PubMed ID: 12438291
[TBL] [Abstract][Full Text] [Related]
24. Effects of the dual endothelin receptor antagonist tezosentan and hypertonic saline/dextran on porcine endotoxin shock.
Somell A; Weitzberg E; Suneson A; Sollevi A; Hjelmqvist H
Acta Physiol (Oxf); 2007 Aug; 190(4):291-302. PubMed ID: 17498196
[TBL] [Abstract][Full Text] [Related]
25. Tezosentan and right ventricular failure in patients with pulmonary hypertension undergoing cardiac surgery: the TACTICS trial.
Denault AY; Pearl RG; Michler RE; Rao V; Tsui SS; Seitelberger R; Cromie M; Lindberg E; D'Armini AM
J Cardiothorac Vasc Anesth; 2013 Dec; 27(6):1212-7. PubMed ID: 23523254
[TBL] [Abstract][Full Text] [Related]
26. Effect of severe renal impairment on the pharmacokinetics and tolerability of the parenteral endothelin antagonist tezosentan.
van Giersbergen PL; Dingemanse J
Int J Clin Pharmacol Ther; 2003 Jun; 41(6):261-6. PubMed ID: 12816178
[TBL] [Abstract][Full Text] [Related]
27. Role of endothelin-1 in mediating changes in cardiac sympathetic nerve activity in heart failure.
Abukar Y; May CN; Ramchandra R
Am J Physiol Regul Integr Comp Physiol; 2016 Jan; 310(1):R94-9. PubMed ID: 26468257
[TBL] [Abstract][Full Text] [Related]
28. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome.
Wong F; Moore K; Dingemanse J; Jalan R
Hepatology; 2008 Jan; 47(1):160-8. PubMed ID: 17886336
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects.
Dingemanse J; Gunawardena KA; van Giersbergen PL
Br J Clin Pharmacol; 2006 Apr; 61(4):405-13. PubMed ID: 16542201
[TBL] [Abstract][Full Text] [Related]
30. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
[TBL] [Abstract][Full Text] [Related]
31. Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension.
Fitzgerald RK; Oishi P; Ovadia B; Ross GA; Reinhartz O; Johengen MJ; Fineman JR
Pediatr Crit Care Med; 2004 Nov; 5(6):571-7. PubMed ID: 15530195
[TBL] [Abstract][Full Text] [Related]
32. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
[TBL] [Abstract][Full Text] [Related]
33. Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure.
Qiu C; Ding SS; Hess P; Clozel JP; Clozel M
J Cardiovasc Pharmacol; 2001 Aug; 38(2):317-24. PubMed ID: 11483881
[TBL] [Abstract][Full Text] [Related]
34. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.
Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF)
JAMA; 2002 Mar; 287(12):1531-40. PubMed ID: 11911755
[TBL] [Abstract][Full Text] [Related]
35. Haemodynamic and neuroendocrine effects of tezosentan in chronic experimental pulmonary hypertension.
Lourenço AP; Vasques-Nóvoa F; Oliveira-Pinto J; Fontoura D; Roncon-Albuquerque R; Leite-Moreira AF
Intensive Care Med; 2012 Jun; 38(6):1050-60. PubMed ID: 22349420
[TBL] [Abstract][Full Text] [Related]
36. Haemodynamic effects of endothelin receptor antagonist, tezosentan, in tumour necrosis factor-alpha treated anaesthetized rats.
Tabrizchi R; Ford CA
Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):156-67. PubMed ID: 12595957
[TBL] [Abstract][Full Text] [Related]
37. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.
Colucci WS; Elkayam U; Horton DP; Abraham WT; Bourge RC; Johnson AD; Wagoner LE; Givertz MM; Liang CS; Neibaur M; Haught WH; LeJemtel TH
N Engl J Med; 2000 Jul; 343(4):246-53. PubMed ID: 10911006
[TBL] [Abstract][Full Text] [Related]
38. Acute cardiopulmonary effects of a dual-endothelin receptor antagonist on oleic acid-induced pulmonary arterial hypertension in dogs.
Wang L; Zhu DM; Su X; Bai CX; Ware LB; Matthay MA
Exp Lung Res; 2004; 30(1):31-42. PubMed ID: 14967602
[TBL] [Abstract][Full Text] [Related]
39. Tezosentan decreases pulmonary artery pressure and improves survival rate in an animal model of meconium aspiration.
Geiger R; Pajk W; Neu N; Maier S; Kleinsasser A; Fratz S; Navarro-Psiha S; Fischer V; Treml B; Loeckinger A
Pediatr Res; 2006 Jan; 59(1):147-50. PubMed ID: 16327003
[TBL] [Abstract][Full Text] [Related]
40. Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan.
Dingemanse J; Halabi A; van Giersbergen PL
J Clin Pharmacol; 2009 Apr; 49(4):455-64. PubMed ID: 19318695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
